The Influence of Cardiovascular Risk Factors on Bone Marrow Mesenchymal Stromal Cell Fitness
Overview
Pharmacology
Authors
Affiliations
Background Aims: In the past, cell transplantation strategies for the treatment of heart failure have shown promising results in experimental and clinical studies. Bone marrow (BM)-derived stem cells represent the most frequently used cell population. Within this heterogeneous cell population, mesenchymal stromal cells (MSC) have been identified to induce therapeutic effects, mainly through paracrine mechanisms. Because of their low frequency in native tissues, in vitro cell culture expansion is mandatory prior to transplantation. We sought to identify patient-specific cardiovascular risk factors influencing the proliferative potential of MSC.
Methods: BM aspirates from 51 patients undergoing elective cardiac surgery were analyzed for MSC frequency and cell culture expansion potential. Fibroblastic colony-forming units (CFU-F) were quantified for culture conditions applying autologous (AS) or fetal bovine serum (FBS) and different basic media. Univariate and multivariate analyzes were performed in order to determine the impact of patient-specific factors on CFU-F numbers.
Results: Expanded MSC showed a specific immune phenotype and displayed adipogenic, chondrogeneic and osteogeneic differentiation potential. CFU-F numbers did not differ under AS or FBS supplementation. Elevated numbers of mononuclear cells, diabetes mellitus, steroid treatment, chronic obstructive pulmonary disease, renal failure, high euroSCORE and impaired left ventricular function were significant determinants for higher CFU-F numbers.
Conclusions: The impact of specific cardiovascular risk factors on MSC fitness could be determined. These results may help to establish patient profiling in order to identify patients suitable for autologous MSC transplantation, and might lead to the identification of disease-related mechanisms of stem cell activation.
Role of Hyperglycemia in the Senescence of Mesenchymal Stem Cells.
Yin M, Zhang Y, Yu H, Li X Front Cell Dev Biol. 2021; 9:665412.
PMID: 33968939 PMC: 8099107. DOI: 10.3389/fcell.2021.665412.
SantAnna R, Eibel B, Markoski M, Rodrigues C, de Salles F, Giusti I Gene Ther. 2019; 27(1-2):40-50.
PMID: 31278371 DOI: 10.1038/s41434-019-0087-2.
Concise Review: Skeletal Muscle as a Delivery Route for Mesenchymal Stromal Cells.
Hamidian Jahromi S, Davies J Stem Cells Transl Med. 2019; 8(5):456-465.
PMID: 30720934 PMC: 6477141. DOI: 10.1002/sctm.18-0208.
van Rhijn-Brouwer F, Gremmels H, Fledderus J, Verhaar M Cell Transplant. 2018; 27(5):765-785.
PMID: 29895169 PMC: 6047272. DOI: 10.1177/0963689717738257.
Schnapper A, Christmann A, Knudsen L, Rahmanian P, Choi Y, Zeriouh M J Anat. 2017; 232(2):283-295.
PMID: 29193065 PMC: 5770329. DOI: 10.1111/joa.12747.